Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL

Bookmark and Share
Published: 9 Dec 2020
Views: 95
Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA

Dr Lori Leslie speaks to ecancer in an online interview for the virtual ASH 2020 meeting about the results of a US retrospective chart review study comparing clinical outcomes among real-world patients with high-risk chronic lymphocytic leukaemia (CLL) receiving first-line ibrutinib or chemoimmunotherapy.

Dr Leslie reports that patients treated with ibrutinib had a longer time to next treatment compared to those treated with chemoimmunotherapy and were more likely to only receive one line of treatment. She concludes that patients with high-risk CLL do not do as well with chemoimmunotherapy and targeted therapies should be the standard of care.

Dr Leslie discusses the potential impact of these findings and what further questions have been raised by the study.